Theralase Technologies (CVE:TLT) Shares Down 3.6% – Here’s Why

Theralase Technologies Inc. (CVE:TLT)’s stock price dropped 3.6% during mid-day trading on Friday . The stock traded as low as C$0.27 and last traded at C$0.27. Approximately 197,449 shares changed hands during trading, an increase of 3% from the average daily volume of 192,614 shares. The stock had previously closed at C$0.28.

Theralase Technologies Price Performance

The firm has a 50 day moving average of C$0.28 and a 200-day moving average of C$0.22. The company has a market cap of C$71.53 million, a P/E ratio of -15.00 and a beta of -0.29. The company has a current ratio of 0.83, a quick ratio of 3.40 and a debt-to-equity ratio of 29.26.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.